Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

PBM Capital Group

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 19
Average round size
info
The average size of a deal this fund participated in
$60M
Portfolio companies 13
Rounds per year 1.46
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.32
Exits 5
Key employees 4

Areas of investment

  • Biotechnology
  • Life Science
  • Therapeutics
  • Genetics
  • Health Care
Summary

The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Charlottesville.

The high activity for fund was in 2019. The usual things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations. The fund is generally included in 2-6 deals every year.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biotechnology, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Candel, Landos Biopharma, ArcherDX. The fund has exact preference in a number of founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the PBM Capital Group, startups are often financed by The Peierls Foundation, Perceptive Advisors, National Securities Corporation. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Longwood Founders Fund, Boulder Ventures. In the next rounds fund is usually obtained by The Peierls Foundation, Sands Capital Ventures, Perceptive Advisors.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of PBM Capital Group:
Typical Co-investors
PBM Capital Group is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after PBM Capital Group:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Altran France, Ile-de-France, Neuilly-sur-seine
Applied Research Council China, Hong Kong, Hong Kong Island
BankDhofar Muscat, Muscat, Oman
Bartlit Beck Herman Palenchar & Scott Chicago, Illinois, United States
Bild Alternative Investments Corporation Canada, Markham, Ontario
Bryant Park Capital New York, New York, United States
CresVentures Lahore, Pakistan, Punjab
DIC Japan, Shizuoka, Shizuoka Prefecture
EVC Thirty One Holdings -
Firlej Kastory Mazowieckie, Poland, Warsaw
Foreign Investment Promotion Board -
Fujian Huamin Industry Group China, Foochow, Fujian
InnoBio Malaysia, Negeri Sembilan, Nilai
MRCF Biomedical Translation Fund -
Quantum Pacific Capital China, Hong Kong, Hong Kong Island
Rite Ventures Stockholm, Stockholm County, Sweden
Sony Startup Acceleration Program Lund, Skane Lan, Sweden
The Bank of Okinawa Japan, Okinawa, Okinawa Prefecture
Transference Fund China, Shanghai
Trifecta Capital California, San Francisco, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

LEXEO Therapeutics

Biotechnology
Life Science
Therapeutics
$100M09 Sep 2021 New York, New York, United States

Xalud Therapeutics

Biotechnology
Health Care
Medical
Neuroscience
Therapeutics
$30M24 Aug 2021 New York, New York, United States

SalioGen Therapeutics

Biotechnology
Life Science
Therapeutics
$20M18 Feb 2021 Burlington, Massachusetts, United States

LEXEO Therapeutics

Biotechnology
Life Science
Therapeutics
$85M07 Jan 2021 New York, United States

Acumen Pharmaceuticals

Biotechnology
Health Diagnostics
$75M20 Nov 2020 California, United States

Taysha Gene Therapies

Biotechnology
Genetics
Life Science
$95M05 Aug 2020 Dallas, Texas, United States

Taysha Gene Therapies

Biotechnology
Genetics
Life Science
$30M29 Apr 2020 Dallas, Texas, United States

Atsena Therapeutics

Biotechnology
Health Care
Therapeutics
$8M01 Apr 2020 Durham, North Carolina, United States

ArcherDX

Biopharma
Biotechnology
Genetics
Life Science
$55M17 Dec 2019 Boulder, Colorado, United States
News
Electronic Sequencing Platform GenapSys Raises $70 Million

– GenapSys is a company developing a highly accurate and scalable electronic sequencing platform.
– The company raised $70m in Series D equity financing.
– The investors in the round included Farallon Capital Management, L.L.C., Soleus Capital, an affiliate of PBM Capital, and additional new investors.
– The proceeds from this financing will be used to continue advancing GenapSys’ semiconductor based next-generation sequencing (NGS) platform.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent PBM Capital Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 19
Average round size 60M
Rounds per year 1.46
Peak activity year 2021
Lead investments 4
Follow on index 0.32
Exits 5
Group Appearance index 0.84

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

LEXEO Therapeutics

Biotechnology
Life Science
Therapeutics
$100M09 Sep 2021 New York, New York, United States

Xalud Therapeutics

Biotechnology
Health Care
Medical
Neuroscience
Therapeutics
$30M24 Aug 2021 New York, New York, United States

SalioGen Therapeutics

Biotechnology
Life Science
Therapeutics
$20M18 Feb 2021 Burlington, Massachusetts, United States

LEXEO Therapeutics

Biotechnology
Life Science
Therapeutics
$85M07 Jan 2021 New York, United States

Acumen Pharmaceuticals

Biotechnology
Health Diagnostics
$75M20 Nov 2020 California, United States

Taysha Gene Therapies

Biotechnology
Genetics
Life Science
$95M05 Aug 2020 Dallas, Texas, United States

Taysha Gene Therapies

Biotechnology
Genetics
Life Science
$30M29 Apr 2020 Dallas, Texas, United States

Atsena Therapeutics

Biotechnology
Health Care
Therapeutics
$8M01 Apr 2020 Durham, North Carolina, United States

ArcherDX

Biopharma
Biotechnology
Genetics
Life Science
$55M17 Dec 2019 Boulder, Colorado, United States
Crunchbase icon

Content report

The following text will be sent to our editors: